



# ANTISENSE THERAPEUTICS

## **Antisense Therapeutics to Present at Rodman & Renshaw 6<sup>th</sup> Annual Healthcare Conference**

**Melbourne, Australia – October 21, 2004** – Antisense Therapeutics Limited (ASX: ANP) today announced that company management will present at the Rodman & Renshaw 6<sup>th</sup> Annual Healthcare Conference at The Waldorf-Astoria Hotel in New York City on Wednesday, October 27, 2004 at 11:50 AM ET.

Mark Diamond, chief executive officer, is scheduled to present to an audience of analysts and portfolio managers. His presentation will include both a company presentation and a moderated discussion between management and institutional investors.

To arrange a one-on-one meeting with Mr. Diamond during the conference, please contact Rachel Levine at The Anne McBride Company, tel. 212-983-1702, ext. 207, or [rlevine@annemcbride.com](mailto:rlevine@annemcbride.com).

### **About Antisense Therapeutics Limited**

Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. ANP's mission is to create, develop and commercialise novel antisense pharmaceuticals for large unmet markets. Its two most advanced projects target Multiple Sclerosis (ATL1102), and Psoriasis (ATL1101).

ANP plans to commercialise its pipeline via licensing/collaboration agreements with major biotechnology and pharmaceutical companies.

ANP's major shareholders include Circadian Technologies Limited (ASX: CIR), Isis Pharmaceuticals Inc (NASDAQ: ISIS) and Queensland Investment Corporation.

### **Contact Information:**

Website: [www.antisense.com.au](http://www.antisense.com.au)

Managing Director – Mark Diamond +61 3 9827 8999

Company Secretary – Natalie Korchev +61 3 9827 8999

Rachel Levine – The Anne McBride Co. – 212-983-1702 ext. 207